Co-morbidity and self medication in schizophrenia: Involvement of endogenous morphine signaling mechanisms

Current Drug Targets

Volumn 13, Issue 11, 2012, Pages 1454-1457

  Kream, Richard M ^a,b   Kuzelova, Hana ^b   Kralickova, Milena ^b   Ptacek, Radek ^b   Stefano, George B ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Catecholamines; Comorbidity; Dopamine; Endogenous morphine; Schizophrenia; Self medication

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; ACETALDEHYDE; CATECHOLAMINE; DOPAMINE; LEVODOPA; MORPHINE; NALOXONE; TETRAHYDROPAPAVEROLINE; UNCLASSIFIED DRUG;

BIOSYNTHESIS; BRAIN REGION; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; COMORBIDITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; HUMAN; NEUROMODULATION; NONHUMAN; ORBITAL CORTEX; PAPAVER SOMNIFERUM; PICTET SPENGLER CONDENSATION; POLYMERIZATION; REVIEW; SCHIZOPHRENIA; SELF MEDICATION; SIGNAL TRANSDUCTION;

COMORBIDITY; DOPAMINE; HUMANS; MORPHINE; SCHIZOPHRENIA; SELF MEDICATION; SIGNAL TRANSDUCTION;

EID: 84866932019     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530198     Document Type: Review

References (53)

1. Reisine T, Bell GI. Molecular biology of opioid receptors. Trends Neurosci 1993;16: 506-10.
2. Reisine T. Opiate receptors. Neuropharmacol 1995; 34: 463-72.
3. Pasternak GW. The Opiate Receptors. New Jersey: Humana Press; 1988.
4. Gintzler AR, Levy A, Spector S. Antibodies as a means of isolating and characterizing biologically active substances: Presence of a non-peptide morphine-like compound in the central nervous system. Proc Natl Acad Sci USA 1976; 73: 2132-6.
5. Gintzler AR, Gershon MD, Spector S. A nonpeptide morphine-like compound: immunocytochemical localization in the mouse brain. Science 1978; 199: 447-8.
6. Stefano GB, Digenis A, Spector S, et al. Opiate-like substances in an invertebrate, an opiate receptor on invertebrate and human immunocytes, and a role in immunosuppression. Proc Natl Acad Sci USA 1993; 90: 11099-103.
7. Cadet P, Mantione KJ, Stefano GB. Molecular identification and functional expression of mu3, a novel alternatively spliced variant of the human mu opiate receptor gene. J Immunol 2003; 170(10): 5118-23.
8. Cadet P, Mantione KJ, Zhu W, Kream RM, Sheehan M, Stefano GB. A functionally coupled mu3-like opiate receptor/nitric oxide regulatory pathway in human multi-lineage progenitor cells. J Immunol 2007; 179(9): 5839-44.
9. Kream RM, Sheehan M, Cadet P, et al. Persistence of evolutionary memory: Primordial six-transmembrane helical domain mu opiate receptors selectively linked to endogenous morphine signaling. Med Sci Monit 2007; 13(12): SC5-6.
10. Kream RM, Stefano GB. De novo biosynthesis of morphine in animal cells: An evidence-based model. Med Sci Monit 2006; 12(10): RA207-19.
11. Boettcher C, Fellermeier M, Boettcher C, Drager B, Zenk MH. How human neuroblastoma cells make morphine. Proc Natl Acad Sci USA 2005; 102(24): 8495-500.
12. Zhu W, Mantione KJ, Shen L, et al. Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: CYP2D6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling. Med Sci Monit 2005; 11: BR397-404.
13. Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize morphine: CYP2D6 modulation. J Immunol 2005; 175(11): 7357-62.
14. Guengerich FP, Miller GP, Hanna IH, Sato H, Martin MV. Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps. J Biol Chem 2002; 277(37): 33711-9.
15. Niwa T, Hiroi T, Tsuzuki D, et al. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res 2004; 129(1-2): 117-23.
16. Stefano GB, Ptacek R, Kuzelova H, Kream RM. Endogenous morphine: Up-to-date review 2011. Folia Biologica: Folia Biol (Praha) 2011; 58(2): 49-56.
17. Zhu W, Mantione KJ, Shen L, Lee B, Stefano GB. Norlaudanosoline and nicotine increase endogenous ganglionic morphine levels: Nicotine addiction. Cell Mol Neurobiol 2006; 26(4-6): 1037-45.
18. Matsubara K, Fukushima S, Akane A, Kobayashi S, Shiono H. Increased urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing L-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans. J Pharmacol Exp Ther 1992; 260(3): 974-8.
19. Cashaw JL. Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography. J Chromatogr 1993; 613(2): 267-73.
20. Walsh MJ, Davis VE, Yamanaka Y. Tetrahydropapaveroline: an alkaloid metabolite of dopamine in vitro. J Pharmacol Exp Ther 1970; 174(3): 388-400.
21. Weiner H. Relationship between 3,4-dihydroxyphenylacetaldehyde levels and tetrahydropapaveroline formation. Alcohol Clin Exp Res 1978; 2(2): 127-31.
22. Sandler M, Carter SB, Hunter KR, Stern GM. Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man. Nature 1973; 241(5390): 439-43.
23. Sango K, Maruyama W, Matsubara K, et al. Enantio-selective occurrence of (S)-tetrahydropapaveroline in human brain. Neurosci Lett 2000; 283(3): 224-6.
24. Stefano GB, Kream RM. Endogenous morphine synthetic pathway preceded and gave rise to catecholamine synthesis in evolution (Review). Int J Mol Med 2007; 20(6): 837-41.
25. Stefano GB, Kream RM. Dopamine, Morphine, and Nitric Oxide: An Evolutionary Signaling Triad. CNS Neurosci Ther 2010; 16: e124-e137.
26. Kream RM, Stefano GB, Rtacek R. Psychiatric Implications of Endogenous Morphine: Up-To-Date Review. Folia Biol (Praha) 2010; 56: 231-41.
27. Comfort A. Morphine as an antipsychotic. Relevance of a 19thcentury therapeutic fashion. Lancet 1977; 2(8035): 448-9.
28. Lindstrom LH, Widerlov E, Gunne LM, Wahlstrom A, Terenius L. Endorphins in human cerebrospinal fluid: clinical correlations to some psychotic states. Acta Psychiatr Scand 1978; 57(2): 153-64.
29. Pickar D, Vartanian F, Bunney WE, Jr., et al. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study. Arch Gen Psychiatry 1982; 39(3): 313-9.
30. Schmauss C, Emrich HM. Dopamine and the action of opiates: a reevaluation of the dopamine hypothesis of schizophrenia. With special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia. Biol Psychiatry 1985; 20(11): 1211-31.
31. Fricchione GL, Mendoza A, Stefano GB. Morphine and its psychiatric implications. Adv Neuroimmunol 1994; 4: 117-32.
32. Lipska BK, Weinberger DR. Cortical regulation of the mesolimbic dopamine system: Implications for schizophrenia. In: Kalivas PW, Barnes CD, editors. Limbic motor circuits and neuropsychiatry. Boca Raton: CRC Press; 1993. p. 329-349m.
33. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992; 149(7): 890-7.
34. Nikulina EM, Miczek KA, Hammer RP, Jr. Prolonged effects of repeated social defeat stress on mRNA expression and function of mu-opioid receptors in the ventral tegmental area of rats. Neuropsychopharmacology 2005; 30(6): 1096-103.
35. Esch T, Stefano GB. The Neurobiology of Love. Neuro Endocrinol Lett 2005; 26(3): 175-92.
36. Stefano GB, Fricchione GL, Esch T. Relaxation: Molecular and physiological significance. Med Sci Monit 2006; 12(9): HY21-31.
37. Stefano GB, Fricchione GL, Goumon Y, Esch T. Pain, immunity, opiate and opioid compounds and health. Med Sci Monit 2005; 11(5): MS47-MS53.
38. Stefano GB, Kream R. Endogenous opiates, opioids, and immune function: evolutionary brokerage of defensive behaviors. Semin Cancer Biol 2008; 18(3): 190-8.
39. Neri C, Ghelardini C, Sotak B, et al. Dopamine is necessary to endogenous morphine formation in mammalian brain in vivo. J Neurochem 2008; 106(61): 2337-44.
40. Bianchi E, Alessandrini C, Guarna M, Tagliamonte A. Endogenous codeine and morphine are stored in specific brain neurons. Brain Res 1993; 627(2): 210-5.
41. Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005; 11(5): 315-39.
42. Smelson DA, Dixon L, Craig T, et al. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs 2008; 22(11): 903-16.
43. Batki SL, Meszaros ZS, Strutynski K, et al. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res 2009; 107(2-3): 139-46.
44. Zhu W, Mantione KJ, Casares FM, et al. Alcohol-, nicotine-, and cocaine-evoked release of morphine from invertebrate ganglia: Model system for screening drugs of abuse. Med Sci Monit 2006; 12(5): BR155-61.
45. Zhu W, Mantione KJ, Casares FM, Sheehan MH, Kream RM, Stefano GB. Cholinergic regulation of endogenous morphine release from lobster nerve cord. Med Sci Monit 2006; 12(9): BR295-301.
46. Carey KB, Leontieva L, Dimmock J, Maisto SA, Batki SL. Adapting Motivational Interventions for Comorbid Schizophrenia and Alcohol Use Disorders. Clin Psychol (New York) 2007; 14(1): 39-57.
47. Zhu W, Mantione K, Kream RM, Stefano GB. Alcohol-, Nicotine-, and Cocaine-Evoked Release of Morphine from Human White Blood Cells: Substances of Abuse Actions Converge on Endogenous Morphine Release. Med Sci Monit 2006; 12(11): BR350-BR354.
48. Batki SL, Dimmock JA, Wade M, et al. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophreniaspectrum disorders. Am J Addict 2007; 16(4): 253-9.
49. Batki SL, Dimmock JA, Ploutz-Snyder R, et al. Naltrexone treatment for patients with schizophrenia and alcohol dependence: The role of adherence-preliminary findings. Alcohol Clin Exp Res 2007; 31(6:suppl): 255A (abstract S028).
50. Semkovska M, Bedard MA, Stip E. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives]. Encephale 2001; 27(5): 405-15.
51. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Metaanalysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry 2009; 66(8): 811-22.
52. Quednow BB, Csomor PA, Chmiel J, Beck T, Vollenweider FX. Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. Int J Neuropsychopharmacol 2008; 11(5): 655-69.
53. Becerra L, Harter K, Gonzalez RG, Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg 2006; 103(1): 208-16, table.